Not an 'excellent outcome' for Athersys stock as stem cell therapy misses endpoint in Japanese trial

Results from a trial by Athersys’ Japanese partner Healios showed that patients with ischemic stroke who received a single dose of the MultiStem therapy did not show a statistically significant achievement of the primary endpoint of an “excellent outcome” at 90 days.